HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare but Targetable Spot Should Not Be Neglected

Guangjian Yang,Yaning Yang,Runze Liu,Jiaqi Hu,Haiyan Xu,Weihua Li,Xuezhi Hao,Yan Wang

DOI: https://doi.org/10.2139/ssrn.4155240

2022-01-01

SSRN Electronic Journal

Abstract:Objectives: Different with the well-known HER2 amplification and exon 20 insertions, missense mutations in the HER2 protein extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are indicated to be oncogenic in non-small cell lung cancer (NSCLC), potentially with diverse responses to HER2 -targeted tyrosine kinase inhibitors (TKIs). However, it lacks current evidence to demonstrate their subtypes and responses to TKIs in NSCLC, with revealing their structural differences.Materials and Methods: Real-world cohort study was performed to collect and investigate targeted outcomes of TKIs for heterogeneous HER2 missense mutations in advanced NSCLC. Computational structures of ECD, TMD and ICD mutations and in silico dynamics simulation were performed to explore their discrepancy.Results: A total of 22 patients (10 harboring ECD mutations, 3 carrying TMD mutation V659E, and 9 with ICD mutations) with available targeted outcome to HER2 -TKIs were included for efficacy evaluation. HER2-targeted TKIs showed similar progression-free survival (PFS) benefit (median, 5.4 vs. 5.0 months, HR=0.666, P =0.421), but more favorable objective response rate (33.3% vs. 8.3%) and disease control rate (88.9% vs. 75.0%) as first- or second-line treatment. Pan-ErbB inhibitor pyrotinib revealed numerically longer PFS (median, 8.6 vs. 5.0 months, HR=0.911, P =0.879) compared with afatinib or dacomitinib in second-line setting. Molecular models and computational simulations of ECD, TMD and ICD mutations revealed discrepant structures.Conclusion: Currently approved HER2-targeted TKIs showed reasonable activity for HER2-activating missense mutations in NSCLC. Clinical awareness of these rare but targetable HER2 mutations might lead to the promising management with targeted therapy in this population.